If the pharmaceutical industry were to conjure a list of fears about what may happen to their US businesses during a democratic administration, Joe Biden’s four years in the White House turned that nightmare into reality.
The Good, The Bad, And The Uncertain: Trump’s Second Administration And The Rx Industry
The pharma industry arguably suffered none of the possible downside risks during the first Trump Administration, but its relationship with Biden could not have been much worse. And while sponsors may hope a Trump return could improve their fortunes, having Robert F. Kennedy Jr. supervising the FDA is likely not the prescription they prefer.
